GGrantIndex
← Leaderboards

Jeffrey Michael Arbeit

University Of California San Francisco

$8,172,913
Attributed
$8,770,810
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $975.5K · FY200515
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15

Funding mix

By agency

NIH$8,770,810 · 6

By mechanism

R01$8,468,252 · 4
U54$302,558 · 1
P30$0 · 1

Top collaborators

Most similar at University Of California San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Laboratory Mouse

Research focus

Laboratory MouseGenetically Modified AnimalsFemaleEstrogensHuman PapillomavirusAngiogenesisChemical CarcinogenesisViral CarcinogenesisHypoxia Inducible Factor 1Cervix NeoplasmsCarcinogenesisTumor Suppressor GenesApoptosisSirolimusCell ProliferationCancer CellTumorMalignant NeoplasmsInhibitor/AntagonistInjection Of Therapeutic AgentAntibodiesImmunodeficient MouseInsightGrowth

Grant awards (25)

PHOTOACOUSTIC MICROSCOPY OF NEOVASCULARIZATION IN RENAL CANCER GROWTH AND THERAPY$588,368
R01 · FY2015 · CA · contact PI
PHOTOACOUSTIC MICROSCOPY OF NEOVASCULARIZATION IN RENAL CANCER GROWTH AND THERAPY$573,291
R01 · FY2014 · CA · contact PI
PHOTOACOUSTIC MICROSCOPY OF NEOVASCULARIZATION IN RENAL CANCER GROWTH AND THERAPY$558,103
R01 · FY2013 · CA · contact PI
PHOTOACOUSTIC MICROSCOPY OF NEOVASCULARIZATION IN RENAL CANCER GROWTH AND THERAPY$596,488
R01 · FY2012 · CA · contact PI
PHOTOACOUSTIC MICROSCOPY OF NEOVASCULARIZATION IN RENAL CANCER GROWTH AND THERAPY$599,307
R01 · FY2011 · CA · contact PI
Small Animal Research Core$179,829
U54 · FY2009 · CA · contact PI
Small Animal Research Core$122,729
U54 · FY2008 · CA · contact PI
Mammalian Target of Rapamycin in Prostate Carcinogenesis$562,905
R01 · FY2007 · CA · contact PI
Mammalian Target of Rapamycin in Prostate Carcinogenesis$566,556
R01 · FY2006 · CA · contact PI
Hypoxia-inducible factor1a in multistage carcinogenesis$391,365
R01 · FY2006 · CA · contact PI
Mammalian Target of Rapamycin in Prostate Carcinogenesis$567,105
R01 · FY2005 · CA
Hypoxia-inducible factor1a in multistage carcinogenesis$408,385
R01 · FY2005 · CA
Mammalian Target of Rapamycin in Prostate Carcinogenesis$559,849
R01 · FY2004 · CA
Hypoxia-inducible factor1a in multistage carcinogenesis$396,490
R01 · FY2004 · CA
Mammalian Target of Rapamycin in Prostate Carcinogenesis$553,212
R01 · FY2003 · CA
Hypoxia-inducible factor1a in multistage carcinogenesis$242,329
R01 · FY2003 · CA
Hypoxia-inducible factor1a in multistage carcinogenesis$139,894
R01 · FY2003 · CA
Hypoxia-inducible factor1a in multistage carcinogenesis$352,857
R01 · FY2002 · CA
ESTROGEN, HPV, AND CERVIX CANCER IN TRANSGENIC MICE$334,467
R01 · FY2001 · CA
ESTROGEN, HPV, AND CERVIX CANCER IN TRANSGENIC MICE$75,960
R01 · FY2001 · CA
Core--Transgenic/targeted mutagenesis$0
P30 · FY2001 · CA
Core--Transgenic/targeted mutagenesis$0
P30 · FY2001 · CA
ESTROGEN, HPV, AND CERVIX CANCER IN TRANSGENIC MICE$327,574
R01 · FY2000 · CA
ESTROGEN, HPV, AND CERVIX CANCER IN TRANSGENIC MICE$73,747
R01 · FY2000 · CA
Core--Transgenic/targeted mutagenesis$0
P30 · FY2000 · CA